PharmaVoice

Pharma Tech

Podcast: Servier describes its M&A and manufacturing strategy amidst deal-making drive

Servier’s head of business development Frederic Scaerou discusses the French company’s recent string of dealmaking.

Pharma Tech

Merck KGaA-backed Cyllene Therapeutics secures €33m for gene therapy pipeline

Fresh with a rebrand, Cyllene will advance gene therapies built on a platform that uses a modified form of the herpes virus for delivery.

Read Full Article

Pharma Tech

De-risking drug formulation with AI predictive modelling

Through predictive modelling, AI supports target identification, prediction of physicochemical properties and formulation strategy selection.

Read Full Article

Pharma Tech

Vertex signs agreement to acquire Crinetics for $10bn

Vertex is to acquire Crinetics Pharmaceuticals in a transaction valued at nearly $10bn, or $8.8bn net of estimated cash acquired.

Read Full Article

Pharma Tech

EC approves AbbVie’s Tepkinly combination for follicular lymphoma

The EC has granted marketing authorisation for AbbVie’s Tepkinly in combination with lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma.

Read Full Article

Featured promotional

Jeplus.in

Purchase All Medicines.Get 10% Offer

News

Latest stories

Pharma Tech

Jul 7, 2026, 3:52 PM

Podcast: Servier describes its M&A and manufacturing strategy amidst deal-making drive

Servier’s head of business development Frederic Scaerou discusses the French company’s recent string of dealmaking.

Read

Pharma Tech

Jul 7, 2026, 2:31 PM

Merck KGaA-backed Cyllene Therapeutics secures €33m for gene therapy pipeline

Fresh with a rebrand, Cyllene will advance gene therapies built on a platform that uses a modified form of the herpes virus for delivery.

Read

PharmaShots

Jul 7, 2026, 1:30 PM

Key Biosimilars Events of June 2026

Shots: Company: Celltrion Product: CT-P55 Active Ingredient: secukinumab Reference Product: Cosentyx Reference Product Company: Novartis Disease: All Approved Indications Date: Jun 01, 2026 Shots: Company: Chime Biologics & Daewoong Product: Dupilumab Active Ingredient: Dupilumab Reference Product: Dupixent Reference Product Company: Sanofi and Regeneron Disease: All Approved Indications Date: Jun 02, 2026 Shots: Company: Polpharma Biologics and PSI CRO Product: PB018 Active Ingredient: Ocrelizumab Reference Product: Ocrevus Reference Product Company: Genentech Disease: All Approved Indications Date: Jun 03, 2026 Shots: Company: Xbrane Product: Lucamzi Active… The post Key Biosimilars Events of June 2026 appeared first on PharmaShots.

Read

PharmaShots

Jul 7, 2026, 12:29 PM

Agios Pharmaceuticals Receives US FDA Priority Review for Mitapivat to Treat Sickle Cell Disease

Shots: Ref: Globenewswire | Image: Agios | Press Release Related News: Agios Pharmaceuticals Licenses Cevidoplenib from Oscotec in a ~$165M Deal PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post Agios Pharmaceuticals Receives US FDA Priority Review for Mitapivat to Treat Sickle Cell Disease appeared first on PharmaShots.

Read

ET Pharma

Jul 7, 2026, 12:06 PM

Patient groups seek inclusion of new cancer drugs in NLEM

The NLEM, compiled by the Ministry of Health, is considered indispensable for meeting India’s public health needs based on their safety, efficacy and cost-effectiveness. The current list includes 384 medicines, which are dispensed free of cost through public health facilities, and are subject to price control.

Read

Pharma Tech

Jul 7, 2026, 11:44 AM